Polymyxin B versus colistin: An update

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 12, 2015, Pages 1481-1497

  Cai, Yiying ^a,c   Lee, Winnie ^a   Kwa, Andrea L ^a,b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

colistimethate sodium; colistin sulfate; multi drug resistance; pharmacokinetics and pharmacodynamics; polymyxin B; polymyxin combination therapy; polymyxins; polypeptide antibiotics

Indexed keywords

ACETYLCYSTEINE; AMIKACIN; ASCORBIC ACID; AZITHROMYCIN; CARBAPENEM DERIVATIVE; CEFTAZIDIME; COLISTIMETHATE; COLISTIN; FLUCONAZOLE; FOSFOMYCIN; MELATONIN; MEROPENEM; MINOCYCLINE; POLYMYXIN; POLYMYXIN A; POLYMYXIN B; POLYMYXIN C; POLYMYXIN D; POLYPEPTIDE ANTIBIOTIC AGENT; PRODRUG; RIFAMPICIN; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ALLERGIC REACTION; BRONCHOSPASM; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; HUMAN; INJECTION PAIN; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OLIGURIA; PHARMACEUTICAL EQUIVALENCE; PRURITUS; REVIEW; URTICARIA; ANIMAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; POLYMYXIN B;

EID: 84949538176     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1093933     Document Type: Review

References (123)

1. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagnos Microbiol infec Dis 2012; 73 (4): 354-60
2. Hsu LY, Tan TY, Tam VH, et al. Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 2010; 54 (3): 1173-8
3. van Duijn PJ, Dautzenberg MJ, Oostdijk EA. Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 2011; 17 (6): 658-65
4. WHO. Antimicrobial resistance: Global report on surveillance 2014 (2014).
5. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72 (6): 857-68
6. Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006; 367 (9511): 633-4
7. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 46: 723-63
8. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007; 5 (5): 811-21
9. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50 (6): 1953-8
10. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (8): 3430-6
11. Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014; 58 (5): 2740-6
12. Stansly PG, Shepherd RG, White HJ. Polymyxin: a new chemotherapeutic agent. Bull Johns Hopkins Hosp 1947; 81 (1): 43-54
13. Katz E, Demain AL. The peptide antibiotics of Bacillus: chemistry, biogenesis, and possible functions. Bacteriol Rev 1977; 41 (2): 449-74
14. Orwa JA, Govaerts C, Busson R, et al. Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 2001; 54 (7): 595-9
15. Orwa JA, Govaerts C, Busson R, et al. Isolation and structural characterization of polymyxin B components. J Chromatogr A 2001; 912 (2): 369-73
16. He J, Ledesma KR, Lam WY, et al. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 2010; 35 (3): 308-10
17. Kassamali Z, Wang W, Jones RN, et al. Is what you see what you get? Product variation in clinical and reference formulations of polymyxin B (Oral Session O581). 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 27-30 April 2013, Berlin, Germany
18. Kwa AL, Tam VH, Falagas ME. Polymyxins: a review of the current status including recent developments. Ann Acad Med Singapore 2008; 37 (10): 870-83
19. Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 2014; 59 (1): 88-94
20. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964; 23: 552-74
21. Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1967; 29 (2): 125-35
22. Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47 (4): 1364-70
23. Dudhani RV, Nation RL, Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 2010; 65 (7): 1412-15
24. Wallace SJ, Li J, Rayner CR, et al. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008; 52 (9): 3047-51
25. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010; 53 (5): 1898-916
26. Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an old class of antibiotics. Future Microbiol 2013; 8 (6): 711-24
27. Schindler M, Osborn MJ. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979; 18 (20): 4425-30
28. Ben-Ami R, Lewis RE, Tarrand J, et al. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 2010; 54 (1): 484-90
29. Zhai B, Zhou H, Yang L, et al. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother 2010; 65 (5): 931-8
30. Guo YB, Chen LP, Cao HW, et al. Polymyxin B antagonizing biological activity of lipopolysaccharide. Chin J Traumatol 2007; 10 (3): 180-3
31. Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Crit Care 2014; 18 (3): 309
32. Pankey G, Ashcraft D, Kahn H, Ismail A. Time-kill assay and Etest evaluation for synergy with polymyxin B and fluconazole against Candida glabrata. Antimicrob Agents Chemother 2014; 58 (10): 5795-800
33. Zeidler U, Bougnoux ME, Lupan A, et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob Chemother 2013; 68 (6): 1285-96
34. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing; Twenty-fifth informational supplement. CLSI document M100-25. Clinical and Laboratory Standards Institute; Wayne, PA: 2015
35. European committee on antimicrobial susceptibility testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. 2015. Available from: www.eucast.org
36. Labreche MJ, Graber CJ, Nguyen HM. Recent updates on the role of pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice. Infec Dis Soc Am 2015. [Epub ahead of print]
37. Lo-Ten-Foe JR, de Smet AM, Diederen BM, et al. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains. Antimicrob Agents Chemother 2007; 51 (10): 3726-30
38. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 2013; 51 (6): 1678-84
39. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011; 203 (4): 545-8
40. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 2014; 5: 643
41. Trent MS, Ribeiro AA, Lin S, et al. An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-L-arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor. J Biol Chem 2001; 276 (46): 43122-31
42. Cheng HY, Chen YF, Peng HL. Molecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43. J Biomed Sci 2010; 17: 60
43. Lee JY, Ko KS. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis 2014; 78 (3): 271-6
44. Rolain JM, Diene SM, Kempf M, et al. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrobial agents and chemotherapy 2013; 57 (1): 592-6
45. Cannatelli A, DAndrea MM, Giani T, et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother 2013; 57 (11): 5521-6
46. Moffatt JH, Harper M, Adler B, et al. Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011; 55 (6): 3022-4
47. Llobet E, Tomas JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 2008; 154 (Pt 12): 3877-86
48. Padilla E, Llobet E, Domenech-Sanchez A, et al. Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. Antimicrob Agents Chemother 2010; 54 (1): 177-83
49. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50 (9): 2946-50
50. Meletis G, Tzampaz E, Sianou E, et al. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 2011; 66 (4): 946-7
51. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67 (7): 1607-15
52. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4 (2): 138-46
53. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55 (7): 3284-94
54. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57 (4): 524-31
55. Cao G, Ali FE, Chiu F, et al. Development and validation of a reversed-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 2008; 62 (5): 1009-14
56. He J, Gao S, Hu M, et al. A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 2013; 68 (5): 1104-10
57. Kwa AL, Lim TP, Low JG, et al. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn Microbiol Infect Dis 2008; 60 (2): 163-7
58. Zavascki AP, Goldani LZ, Cao G, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47 (10): 1298-304
59. Sandri AM, Landersdorfer CB, Jacob J, et al. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother 2013; 68 (3): 674-7
60. Li J, Coulthard K, Milne R, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003; 52 (6): 987-92
61. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30 (1): 143-51
62. Couet W, Gregoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011; 89 (6): 875-9
63. Mizuyachi K, Hara K, Wakamatsu A, et al. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr Med Res Opin 2011; 27 (12): 2261-70
64. Healy DP, Sombun AD, Gardner JC, et al. Pharmacokinetics of colistin in an adolescent boy with extensive burn injury. J Burn Care Res 2011; 32 (1): e7-11
65. Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother 2012; 67 (10): 2459-62
66. Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 2014; 58 (1): 440-6
67. Gregoire N, Mimoz O, Megarbane B, et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 2014; 58 (12): 7324-30
68. Akers KS, Rowan MP, Niece KL, et al. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration. Antimicrob Agents Chemother 2015; 59 (1): 46-52
69. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56 (8): 4241-9
70. Kassamali Z, Rotschafer JC, Jones RN, et al. Polymyxins: wisdom does not always come with age. Clin Infect Dis 2013; 57 (6): 877-83
71. Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 2015; 15 (2): 225-34
72. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007; 59 (3): 473-7
73. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49 (9): 3624-30
74. Poudyal A, Howden BP, Bell JM, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62 (6): 1311-18
75. Bulitta JB, Yang JC, Yohonn L, et al. Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother 2010; 54 (5): 2051-62
76. Hengzhuang W, Hoiby N, Ciofu O. Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo. Methods Mol Biol 2014; 1147: 239-54
77. Plachouras D, Giamarellos-Bourboulis EJ, Kentepozidis N, et al. In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007; 57 (4): 419-22
78. Bozkurt-Guzel C, Gerceker AA. In vitro pharmacodynamic properties of colistin methanesulfonate and amikacin against Pseudomonas aeruginosa. Indian J Med Microbiol 2012; 30 (1): 34-8
79. Bergen PJ, Bulitta JB, Forrest A, et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 2010; 54 (9): 3783-9
80. Dudhani RV, Turnidge JD, Nation RL, Li J. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010; 65 (9): 1984-90
81. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54 (3): 1117-24
82. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60 (6): 1206-15
83. Dubrovskaya Y, Prasad N, Lee Y, et al. Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 2015; 70 (6): 1903-7
84. Wertheim H, Van Nguyen K, Hara GL, et al. Global survey of polymyxin use: A call for international guidelines. J Glob Antimicrob Resist 2013; 1 (3): 131-4
85. Biswas S, Brunel JM, Dubus JC, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012; 10 (8): 917-34
86. Shahbazi F, Dashti-Khavidaki S. Colistin: efficacy and safety in different populations. Expert Rev Clin Pharmacol 2015; 8 (4): 423-48
87. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012; 54 (12): 1720-6
88. Yapa WSS, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 2014; 58 (5): 2570-9
89. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008; 102 (3): 407-12
90. Antonelli M, Ronco C. Polymyxin B hemoperfusion in sepsis: growing body of evidence and occasional conflicting results. Blood Purif 2015; 39 (1-3): I-II
91. Nanjo Y, Ishii Y, Kimura S, et al. Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis. J Infect Chemother 2013; 19 (4): 683-90
92. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14 (9): 816-27
93. Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 2015; 45 (1): 8-18
94. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54 (12): 5316-22
95. Lim TP, Lee W, Tan TY, et al. Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B. PLoS One 2011; 6 (12): e28177
96. Lim TP, Cai Y, Hong Y, et al. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59 (5): 2515-24
97. Chua NG, Zhou YP, Tan TT, et al. Polymyxin B with dual carbapenem combination therapy against carbapenemase-producing Klebsiella pneumoniae. J Infect 2015; 70 (3): 309-11
98. Gaibani P, Lombardo D, Lewis RE, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 2014; 69 (7): 1856-65
99. Barth N, Ribeiro VB, Zavascki AP. In vitro activity of polymyxin b plus imipenem, meropenem, or Tigecycline against KPC-2-producing enterobacteriaceae with High MICs for these antimicrobials. Antimicrob Agents Chemother 2015; 59 (6): 3596-7
100. Krishnappa LG, Marie MA, Al Sheikh YA. Characterization of carbapenem resistance mechanisms in Klebsiella pneumoniae and in vitro synergy of the colistin-meropenem combination. J Chemother 2014; 27 (5): 277-82
101. Tang HJ, Ku YH, Lee MF, et al. In Vitro Activity of Imipenem and Colistin against a Carbapenem-Resistant Klebsiella pneumoniae Isolate Coproducing SHV-31, CMY-2, and DHA-1. Biomed Res Int 2015; 2015: 568079
102. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69 (9): 2305-9
103. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infec 2014; 33 (8): 1311-22
104. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (4): 2322-8
105. Ni W, Cai X, Wei C, et al. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Br J Infec Dis 2015; 19 (2): 170-80
106. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57 (3): 349-58
107. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015; 35 (1): 28-33
108. Moestrup SK, Cui S, Vorum H, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96 (3): 1404-13
109. Abdelraouf K, Braggs KH, Yin T, et al. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012; 56 (9): 4625-9
110. Dai C, Li J, Tang S, et al. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents Chemother 2014; 58 (7): 4075-85
111. Yousef JM, Chen G, Hill PA, et al. Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 2012; 67 (2): 452-9
112. Yousef JM, Chen G, Hill PA, et al. Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 2011; 55 (9): 4044-9
113. Ozyilmaz E, Ebinc FA, Derici U, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 2011; 37 (1): 141-6
114. Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Preliminary clinical study of the effect of ascorbic Acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother 2015; 59 (6): 3224-32
115. Akajagbor DS, Wilson SL, Shere-Wolfe KD, et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infec Dis 2013; 57 (9): 1300-3
116. Rigatto MH, Behle TF, Falci DR, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 2015; 70 (5): 1552-7
117. Elias LS, Konzen D, Krebs JM, Zavascki AP. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010; 65 (10): 2231-7
118. Shrestha A, Soriano SM, Song M, Chihara S. Intravenous colistin-induced acute respiratory failure: A case report and a review of literature. Int J Crit Illn Inj Sci 2014; 4 (3): 266-70
119. Duncan DA. Colistin toxicity. Neuromuscular and renal manifestations. Two cases treated by hemodialysis. Minn Med 1973; 56 (1): 31-5
120. Kubikowski P, Szreniawski Z. The Mechanism of the Neuromuscular Blockade by Antibiotics. Arch Int Pharmacodyn Ther 1963; 146: 549-60
121. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10 (1): R27
122. Kassamali Z, Danziger L. To B or not to B, that is the question: is it time to replace colistin with polymyxin B? Pharmacotherapy 2015; 35 (1): 17-21
123. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 2013; 11 (12): 1333-53